Abstract
The ultimate goal or objective of drug research is the discovery and development of new drugs or the derivation of more information about existing drugs such that the diagnosis, treatment or prevention of diseases of humans and animals can be more effectively accomplished. The development phase includes research activities that are required to convert a drug discovery to a drug product designed to fulfil the objectives of the drug research. From an idealized perspective, these objectives should be met such that the product or service accomplishments could be made available to all those who can benefit from them. Goals easily expressed in such terms can be subscribed to universally.
The author is solely responsible for interpretations and opinions expressed in this article.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
4.1 R&D — Trends, Impact of Regulations, Cost, Productivity
Molecular Modification in Drug Design, Adv. Chem. Ser. 45 ( American Chemical Society, Washington, D.C., 1964 ).
R.G. Denkewalter and M. Tishler, Drug Research — Whence and Whither, in: Progress in Drug Research, Vol. 10 (Ed. E. Jucker; Birkhauser, Basel 1966 ), p. 11.
The Administration of Research Grants in the Public Health Service, 9 th Report by the Committee on Government Operations, House of Representatives (1967). Superintendent of Documents, US Government Printing Office, Washington, D.C.
C. J. Cavallito, Contributions of Medicinal Chemistry to Medicine - From 1935, in: Progress in Drug Research, Vol. 12 (Ed. E. Jucker; Birkhauser, Basel 1968 ), p. 11.
Medicinal Chemistry, 3rd ed., parts I and II (Ed. A. Burger; Wiley-Interscience, New York 1970 ).
Drug Discovery — Science and Development in a Changing Society, Adv. Chem. Ser. 108 ( American Chemical Society, Washington, D.C., 1971 ).
Decision-Making on the Efficacy and Safety of Drugs, Philosophy and Technology of Drug Assessment, Vols. 1, 2 (Ed. J.D. Cooper; Interdisciplinary Communication Associates, Inc., Washington, D.C., 1971 ). ( The Smithsonian Institution. )
G. de Stevens, The Future of Drug Research, Med. Market. Media 6, 24 (1971).
The Development and Control of New Drug Products, Proceedings of 1971 Symposium (Eds. M. Pernarowski and M. Darrach; Evergreen Press, Ltd., Vancouver, B.C. 1972 ).
H. A. Clymer, The Economics of Drug Innovation, ibid, p. 109–127.
A. J. Gordon and S.G. Gilgore, The Art and Science of Contemporary Drug Development, in: Progress in Drug Research, Vol. 16 (Ed. E. Jucker; Birkhauser, Basel 1972 ), p. 194.
L. Lasagna, Research, Regulation, and Development of New Pharmaceuticals: Past, Present, and Future, Am. J. Med. Sci. 263, part 1, p. 8; part 2, p. 66 (1972).
How Modern Medicines are Discovered (Ed. F.H. Clarke; Futura Publishing Co., Mt. Kisco, N.Y., 1973 ).
D. G. Davey, The Concern Over Drug Safety and Its Implications for the Industry’s Innovation and Growth, Chem. Ind. 2, 508 (1973).
L.L. Duetsch, Research Performance in the Ethical Drug Industry, Marq. Business Rev. 17, 129 (1973).
Economic Aspects of R.&D. Intensity in the Pharmaceutical Industry (J.J. Friedman & Associates, Washington, D.C., 1973, Composite Profile of Six Major Companies).
Regulating New Drugs (Ed. R.L. Landau; The University of Chicago Center for Policy Study, The University of Chicago, 1973 ).
S. Peltzman, An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments, J. Polit. Econ. 81, 1049 (1973).
M. Tishler, Drug Discovery — Background and Foreground, Clin. Pharmac. Ther. 14, 479 (1973). Development and Introduction of New Cardiovascular Drugs (Symposium), Am. J. Cardiol. 34, 457 (1974).
B. M. Bloom, The Rate of Contemporary Drug Discovery, Adv. Drug Res. 8, 1 (1974).
S.L. Defelice, An Analysis of the Relationship between Human Experimentation and Drug Discovery in the U.S., Drug Metab. Rev. 3, 167 (1974).
P. de Haen, Current Trends in the Introduction of New Drugs, Clin. Pharmac. Ther. 16, 413 (1974).
C. C. Edwards, The Role of Government and F.&D.A. Regulations in Drug R.&D., Res. Manag. 17, 21 (1974).
L.E. Hollister, The F.&D.A. Ten Years After the Kefauver Harris Amendments, Perspec. Biol. Med. 18, 242 (1974).
S. Peltzman, Regulations of Pharmaceutical Innovation, the 1962 Amendments ( American Enterprise Institute for Public Policy Research, Washington, D.C., 1974 ).
L.H. Sarett, F.D.A. Regulations and Their Influence on Future R.&D., Res. Manag. 17, 18 (1974).
W.M. Wardell, Clin. Pharmac. Ther. 14, 773, 1022 (1973); 15, 73 (1974). (Drug Lag, Therapeutic Implications, U.S. vs. U.K. Comparisons, etc.); also J. Am. Med. Ass. 229, 1457 (1974).
C. J. Cavallito, Interactions of Science, Economics and Politics in Drug Discovery, Development and Delivery, Drug Development Communications, 1, 259 (1974–1975).
Pharmaceutical Manufacturers Association, Washington, D.C., Annual Survey Report 1973–74 (1975), annually early each year.
Research and Development, Road Maps of Industry No. 1763, The Conference Board, New York, N.Y. (June 1975 ).
The Role of the National Institutes of Health, Fed. Proc. 34, ii–iv (1975).
L. Goldman, Is F.D.A. Bureaucracy Depriving U.S. Patients of Useful Drugs, Modern Med. June 1, 41 (1975).
P. de Haen, New Drug Introduction 1973-1974, J. Am. Med. Ass. 234, 728 (1975).
P. de Haen, The Drug Lag — Does it Exist in Europe, Drug Intell. Clin. Pharm. 3, 144 (1975).
Drug Development and Marketing, American Enterprise Institute for Public Policy Research, Washington, D.C., 1975, Ed. R.B. Helms, Major contents: Medical Benefits and Risks Associated with Prescription Drugs: Facts and Fancy, K.L. Melmon, L.B. Sheiner and B. Rosenberg; The Diffusion of Pharmaceutical Information, S. Peltzman; Coping with Illness: Choices, Alternatives, and Consequences, M.B. Balter; Pharmaceutical R&D Expenditures and Rates of Return, D. Schwartzman; The Profit Rates and Economic Performance of Drug Firms, R. Ayanian; Profitability Measures in the Pharmaceutical Industry, T.R. Stauffer; The Economic and Regulatory Climate: U.S. and Overseas Trends, H.A. Clymer: The Rate of New Drug Discovery, L. Lasagna and W. M. Wardell; Developments in the Introduction of New Drugs in the United States and Britain, 1971–74, W.M. Wardell; The Supply Response to Shifting Demand in the Ethical Pharmaceutical Industry, L. G. Telser; Product Innovation and the Dynamic Elements of Competition in the Ethical Pharmaceutical Industry, D.L. Cocks; The Follow-On Development Process and the Market for Diuretics, B. A. Kemp.
J. Maddox, Pharmaceutical Research and Public Ownership, Assoc. British Pharmaceut. Industry, White Crescent Press Ltd., Luton, England, 1975.
F.G. McMahon, Europeanization of American Drug Discovery, Clin. Pharmac. Ther. 18, 375 (1975).
D. Schwartzman, The Expected Return from Pharmaceutical Research ( American Enterprise Institute for Public Policy Research, Washington, D.C., 1975 ).
W.M. Wardell and L. Lasagna, Regulation and Drug Development ( American Enterprise Institute for Public Policy Research, Washington, D.C., 1975 ).
R.&D. Grows 11% in Austere Ford Budget, Chem. Eng. News 54, 12 (1976).
Chemistry in Medicine (American Chemical Society, Washington, D.C.), in press (1976).
4.2 Drug Product Quality, Equivalence, Utilization
Pharmaceutical Preparations, Except Biologicals. Current Industrial Reports (U.S. Dept. of Commerce, Bureau of the Census Industry Division, Washington, D.C.), annually.
Drug Product Quality, Acad. Pharm. Sci., Am. Pharm. Ass., Washington, D.C. (1969).
White Paper on the Therapeutic Equivalence of Chemically Equivalent Drugs, J. Am. Med. Ass. 208, 1171 (1969).
C.J. Cavallito, Therapeutic (?) Equivalence, N.A.R.D. J. 91 (2), 29 (1969).
C. C. Edwards, The F.D.A.’s Views on Generic Equivalence and Drug Quality, Pharm. Times, June 1970, p. 46.
J. G. Wagner, Biopharmaceutics and Relevant Pharmacokinetics (Drug Intelligence Publications, Hamilton, 111., 1971 ).
Report of the Ad Hoc Committee on Drug Product Selection of the Acad. Gen. Practice Pharmacy and the Acad. Pharmaceut. Sciences, J. Am. Pharm. Ass. NS13, 278 (1973).
D. J. Chodos and A.R. Disanto, Basics of Bioavailability ( The Upjohn Company, Kalamazoo, Mich., 1973 ).
H. E. Simmons, Assuring Total Drug Quality, J. Am. Pharm. Ass. NS13, 96 (1973).
Considerations in the Development of Drug Products Formularies, Acad. Pharm. Sci., Am. Pharm. Ass., Washington, D.C. (1974).
Drug Bioequivalence, A Report of the Office of Technology Assessment, Drug Bioequivalence Study Panel (1974). Superintendent of Documents, U.S. Government Printing Office, Washington, D.C.
The Scientific Evaluation of Drug Equivalency (Ed. A.N. Brest: Proceedings and Abstracts of a Colloquium, Washington, D.C., June 14, 1974). Excerpta Medica (1974).
Bioequivalence/Bioavailability, Food Drug Cosmetic Law J., 31, The F.D.A.’s Plans, R.L. Spencer, 32; A Manufacturer’s View, C.J. Cavallito, 39; The Basic Legal and Philosophical Issues, S.J. Land, 46.
4.3 Some Recent Regulations, Proposals, and Government Reviews
F.D.A. Proposed Bioavailability Requirements, Fed. Register 38, 885–887 ( Washington, D.C., 1973 ).
Maximum Allowable Cost for Drugs, Fed. Register 39, 40302 (Washington, D.C., 1974 ).
F.D. A.’s Freedom of Information Regs., Fed. Register 39, 44602–44657 ( Washington, D.C., 1974 ).
Use of Advisory Committees by the Food and Drug Administration, Hearings before the Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, March 6–8, 12, 13; April 30; May 21 ( 1974 ). Superintendent of Documents, US Government Printing Office, Washington, D.C.
F.D.A.’s Freedom of Information Regs., Fed, Register 39, 44602–44657 (Washington, D.C., 1974).
F.D.A. Bioavailability Requirements; Withdrawal of Proposed Rule Making. Conditions for Marketing Human Prescription Drugs, Fed. Register 40, 26142–26171 (1975). Withdrawal of (preceding) Interim Enforcement Policy, Fed. Register 40, 43531–43533 (Washington, D.C., 1975 ).
WHO Assumes Lead in Regulation of International Drug Marketing, Monitor, Nov. 1975, 30 ( Monitor Publications, Washington, D.C. ).
J.R. Crout, Outline of Drug Regulation System, 1975, reprinted in F.D.C. Reports 38, No. 9, 9–18 (1976).
Human and Veterinary Drugs. Current Good Manufacturing Practice in Manufacture, Processing, Packing, or Holding (proposed revisions), Fed. Register 41, 6878–6894 (1976).
4.4 Some ‘Public’ Voices and Expressions
In Whose Hands, Economic Priorities Report, Council on Economic Priorities, New York, N.Y. (1973).
New Drugs in Humans. Notice of Availability of Health Research Group Petition on Investigational Use, Fed. Register 39, 13797 (1974).
T. Alexander, Battered Pillars of the American System: Science, Fortune 91, 146 (1975).
P.J. Brown, Drug Carcinogenicity Studies - The Need for a Code of Conduct, Scrip, 175 (Richmond, Surrey, England; Oct. 4, 1975 ), p. 10–12.
R. Revelle, The Scientist and the Politician, Science 187, 1100 (1975).
L. Tyrmand, The Media Shangri-La, Am. Schol. 45, 753 (1975/76).
A.M. Weinberg, Science in the Public Forum: Keeping it Honest, Science 191, 341 (1976).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Birkhäuser Verlag, Basel
About this chapter
Cite this chapter
Cavallito, C.J. (1976). Changing Influences on Goals and Incentives in Drug Research and Development. In: Jucker, E. (eds) Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrés des recherches pharmaceutiques. Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrés des recherches pharmaceutiques, vol 20. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7094-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7094-8_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0348-7096-2
Online ISBN: 978-3-0348-7094-8
eBook Packages: Springer Book Archive